Hidradenitis Suppurativa (HS)
Pipeline by Development Stage
Drug Modality Breakdown
Dermatology is a $292M market that is mature and consolidating, dominated by a single blockbuster approaching loss of exclusivity.
Key Trends
- HUMIRA (adalimumab) dominates 88% of market spending but faces LOE in near-term, creating vulnerability
- Novel mechanisms like aryl hydrocarbon receptor agonists gaining traction with emerging products in peak lifecycle
- Substantial clinical trial activity (812 trials) suggests ongoing innovation pipeline despite mature market
Career Verdict
Dermatology offers stable near-term opportunities but requires strategic positioning given patent cliff risk and limited market size compared to other therapeutic areas.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | HUMIRA (adalimumab) | AbbVie | $258M | 88% | LOE_APPROACHING | Declining | |
| 2 | VTAMA (tapinarof) | Merck & Co. | $19M | 6% | PEAK | Growing | 13.5yr |
| 3 | ORACEA (doxycycline) | Galderma | $4M | 1% | LOE_APPROACHING | Declining | 1.6yr |
Drug Class Breakdown
Patent cliff looming
Emerging innovation
Mature segment
Niche applications
Career Outlook
StableDermatology represents a stable but narrow career path with limited growth compared to larger therapeutic areas; compensation is competitive in Commercial and Medical Affairs but R&D opportunities are scarce. HUMIRA's patent cliff creates near-term uncertainty for AbbVie but may drive restructuring and new product launches elsewhere. Market consolidation around a few large players (AbbVie, Regeneron, Merck) limits startup/biotech opportunities.
Breaking In
Enter via Commercial or Medical Affairs roles where hiring is highest; dermatology has lower scientific barrier to entry than oncology but requires strong relationship-building and market access acumen.
For Experienced Professionals
Leverage HUMIRA transition expertise or develop specialty in emerging mechanisms (retinoids, AhR agonists); consider moving to larger franchises (immunology, oncology) if seeking higher growth trajectory.
In-Demand Skills
Best For
Hiring Landscape
Dermatology shows concentrated hiring at AbbVie (52 positions) and Regeneron (46 positions), with Commercial roles dominating (89 jobs, $188K avg salary) and Medical Affairs roles commanding premium compensation ($386K avg). Limited R&D hiring (8 positions) suggests mature drug development phase with emphasis on commercialization and market access.
By Department
Commercial and Medical Affairs roles offer strong compensation and growth, but overall job market is small; best for professionals seeking revenue-generating functions rather than discovery roles.
On Market (1)
Approved therapies currently available
Competitive Landscape
12 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 18 trials with date data
Clinical Trials (19)
Total enrollment: 3,615 patients across 19 trials
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
A Study With CIT-013 in HS Patients
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013
Managed Access Programs for AIN457, Secukinumab
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects
Related Jobs in Dermatology
Specialty Sales Representative (Indianapolis, IN)
Territory Manager - Bakersfield
Process Expert (m/f/d) - Schaftenau, Tirol
Territory Manager - Chicago South
Specialty Sales Representative (Birmingham, AL - West)
District Manager
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.